The present invention is directed to methods of killing cancer cells, themethods comprising administering at leastone C35 antibody and either at least one HER2 or at least one EGFR antibody.In some embodiments, the antibodies are administeredwith a therapeutic agent. The present invention is further directed to C35,HER2 and EGFR antibodies useful in these methods.